BVF as of June 30, 2015
Portfolio Holdings for BVF
BVF holds 30 positions in its portfolio as reported in the June 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Array BioPharma | 11.7 | $66M | 9.2M | 7.21 | |
| Chemocentryx | 10.6 | $60M | 7.3M | 8.23 | |
| Blueprint Medicines (BPMC) | 7.4 | $42M | 1.6M | 26.49 | |
| Forward Pharma A/s | 6.8 | $38M | 1.0M | 38.05 | |
| Concert Pharmaceuticals I equity | 6.6 | $38M | 2.5M | 14.89 | |
| Oncothyreon | 6.4 | $37M | 9.8M | 3.74 | |
| Exelixis Inc cnv | 6.0 | $34M | 38M | 0.89 | |
| Loxo Oncology | 5.1 | $29M | 1.6M | 18.03 | |
| Oncomed Pharmaceuticals | 5.0 | $29M | 1.3M | 22.50 | |
| Ironwood Pharmaceuticals (IRWD) | 4.6 | $26M | 2.2M | 12.06 | |
| Vitae Pharmaceuticals | 4.1 | $23M | 1.6M | 14.40 | |
| Tobira Therapeutics Inc Common Stock Usd 0.0001 | 3.6 | $20M | 1.2M | 17.25 | |
| Targacept | 3.3 | $19M | 6.7M | 2.79 | |
| GTx | 2.8 | $16M | 11M | 1.47 | |
| Qlt | 2.7 | $15M | 3.7M | 4.13 | |
| Cytokinetics (CYTK) | 2.5 | $14M | 2.1M | 6.72 | |
| Exelixis (EXEL) | 1.8 | $10M | 2.8M | 3.76 | |
| ArQule | 1.8 | $10M | 6.4M | 1.60 | |
| Seattle Genetics | 1.7 | $9.7M | 200k | 48.40 | |
| Xenon Pharmaceuticals (XENE) | 1.4 | $7.8M | 679k | 11.53 | |
| Five Prime Therapeutics | 1.1 | $6.0M | 241k | 24.84 | |
| Array Biopharma Inc note 3.000% 6/0 | 0.6 | $3.2M | 2.5M | 1.27 | |
| Catabasis Pharmaceuticals | 0.5 | $2.7M | 225k | 12.21 | |
| Mast Therapeutics | 0.4 | $2.5M | 5.1M | 0.49 | |
| Atyr Pharma Inc Common Stock Usd 0.001 | 0.4 | $2.5M | 135k | 18.52 | |
| OncoGenex Pharmaceuticals | 0.4 | $2.4M | 1.0M | 2.33 | |
| Globeimmune (GBIM) | 0.3 | $1.8M | 678k | 2.61 | |
| Biota Pharmaceuticals | 0.1 | $726k | 351k | 2.07 | |
| Achaogen | 0.1 | $643k | 107k | 6.03 | |
| Aptose Biosciences | 0.1 | $538k | 105k | 5.10 |
